Survival Rate
Research News and Information

Saturday, November 21, 2009

Assessment of liver graft function and regeneration by galactosyl-human serum albumin (99mTc-GSA) liver scintigraphy in adult living-donor liver transplantation.

14 Dec 2009 BACKGROUND: In adult living-donor liver transplantation (LDLT), the assessment of the graft functional reserve is very important. We evaluated the graft functional reserve by technetium-99m-diethylenetriaminepenta-acetic acid-galactosyl-human serum ... Read more...

Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.

29 Nov 2009 Our previous study has suggested that the cell cycle-related kinase (CCRK) is a putative candidate oncogene in glioblastoma tumorigenesis. The potential oncogenic role of CCRK and its clinical/prognostic significance, however, in ovarian carcinoma ... Read more...

Model-based projections for deriving up-to-date cancer survival estimates: an international evaluation.

29 Nov 2009 Model-based projections were shown to be useful for deriving most up-to-date population-based cancer survival estimates. However, the performance of these projections, which can be derived by various approaches, has only been evaluated in very few ... Read more...

Latest indexed articles for 'Survival Rate'

These are the very latest articles for this heading:

• Assessment of liver graft function and regeneration by galactosyl-human serum albumin (99mTc-GSA) liver scintigraphy in adult living-donor liver transplantation. 14 Dec 2009
• Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. 29 Nov 2009
• Model-based projections for deriving up-to-date cancer survival estimates: an international evaluation. 29 Nov 2009
• IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. 29 Nov 2009
• Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. 29 Nov 2009
• Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms and gastric cancer risk: a prospective study of men in Shanghai, China. 29 Nov 2009
• Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. 29 Nov 2009
• p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. 29 Nov 2009
• Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. 29 Nov 2009
• Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. 29 Nov 2009
• Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. 29 Nov 2009
• Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. 29 Nov 2009
• Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. 29 Nov 2009
• mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. 29 Nov 2009
• WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. 29 Nov 2009
• Results of treatment methods in cardiac arrest following coronary artery bypass grafting. 16 Nov 2009
• Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. 13 Nov 2009
• Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. 13 Nov 2009
• Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. 13 Nov 2009
• Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. 13 Nov 2009

See a longer list of these articles.

Technical information about 'Survival Rate'

Definition: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.

Descriptor UI: D015996

Alternative terms: Survival Rate; Rate, Survival; Rates, Survival; Survival Rates; Survivorship; Mean Survival Time; Mean Survival Times; Survival Time, Mean; Survival Times, Mean; Time, Mean Survival; Times, Mean Survival; Cumulative Survival Rate; Cumulative Survival Rates; Rate, Cumulative Survival; Rates, Cumulative Survival; Survival Rate, Cumulative; Survival Rates, Cumulative;

Allowable Qualifiers: trends;

Tree Number: E05.318.308.985.550.900; L01.280.975.550.900; N01.224.935.698.826; N06.850.505.400.975.550.900; N06.850.520.308.985.550.900;

History Note: 90

Technical Notes: IM GEN only; coord NIM with disease /mortal (IM); specify geog if pertinent